December 22, 2025

Eliminating Barriers to Care for Patients With Intellectual and/or Developmental Disabilities

A recent large, retrospective study by Giblon et al has found that individuals with intellectual and/or developmental disabilities face an increased risk of developing cancer, higher symptom burden on...

The ASCO Post

December 17, 2025

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.

Dana-Farber

December 17, 2025

Promising Data For Off-the-Shelf Gene-edited Cell Therapy

New clinical results outline patient responses to a donor-derived, gene-edited cell therapy in relapsed and refractory T-cell leukemia

The Medicine Maker

December 15, 2025

Mandibular Aspergillus Osteomyelitis

Authors report rare case in a 13-year-old with hematologic malignancy.

Conexiant

December 12, 2025

Adding Tucatinib to First-Line Maintenance Therapy Delays Disease Progression in HER2-Positive Metastatic Breast Cancer

Adding the selective HER2 inhibitor tucatinib to first-line maintenance therapy with trastuzumab and pertuzumab delayed disease progression in patients with HER2-positive metastatic breast cancer, pot...

The ASCO Post

December 12, 2025

Acupuncture May Improve Perceived Cognitive Difficulties in Breast Cancer Survivors

New findings from the phase II ENHANCE clinical trial indicate that both real and sham acupuncture improve breast cancer survivors’ perceived cognitive impairment more effectively than usual care alon...

The ASCO Post

May 16, 2022

Evaluation of Emergency Department Visits by Oncology Patients: A Running Comparison to Admissions and ED Visits Under the CMS OP-35 Ruling

An analysis reveals 37.5% of emergency visits by cancer patients may be preventable through better care practices—insights from the University of Arizona Cancer Center.

JADPRO

December 04, 2025

Dana-Farber researchers present findings at 2025 San Antonio Breast Cancer Symposium

Physician scientists from Dana-Farber Cancer Institute will present more than 50 research studies at the 48th annual San Antonio Breast Cancer Symposium, December 9-12.

Dana-Farber

November 20, 2025

Dana-Farber Research Opens the Door to Finding More Effective Treatments for Ewing Sarcoma

In 2014, Dana-Farber pediatric oncologist Brian Crompton, MD, discovered that a gene called STAG2 is mutated in about 15 percent of patients with Ewing sarcoma, a form of bone cancer that largely occurs in children and adolescents. 

Dana-Farber